Concomitant analysis of EZH2 and ASXL1 mutations in myelofibrosis, chronic myelomonocytic leukemia and blast-phase myeloproliferative neoplasms

Leukemia. 2011 Jul;25(7):1200-2. doi: 10.1038/leu.2011.58. Epub 2011 Apr 1.
No abstract available

Publication types

  • Letter
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Aged
  • Amino Acid Substitution
  • Blast Crisis / genetics*
  • Blast Crisis / mortality
  • Cohort Studies
  • DNA, Neoplasm / genetics
  • DNA-Binding Proteins / genetics*
  • Dioxygenases
  • Enhancer of Zeste Homolog 2 Protein
  • Exons / genetics
  • Female
  • Genotype
  • Germ-Line Mutation
  • Humans
  • Leukemia, Myelomonocytic, Chronic / genetics*
  • Leukemia, Myelomonocytic, Chronic / mortality
  • Male
  • Mutation, Missense
  • Myeloproliferative Disorders / genetics*
  • Myeloproliferative Disorders / mortality
  • Myeloproliferative Disorders / pathology
  • Neoplasm Proteins / genetics*
  • Polycomb Repressive Complex 2
  • Polymorphism, Single Nucleotide
  • Primary Myelofibrosis / genetics*
  • Primary Myelofibrosis / mortality
  • Prognosis
  • Proto-Oncogene Proteins / genetics
  • Repressor Proteins / genetics
  • Sequence Analysis, DNA
  • Transcription Factors / genetics*

Substances

  • ASXL1 protein, human
  • DNA, Neoplasm
  • DNA-Binding Proteins
  • Neoplasm Proteins
  • Proto-Oncogene Proteins
  • Repressor Proteins
  • Transcription Factors
  • Dioxygenases
  • TET2 protein, human
  • EZH2 protein, human
  • Enhancer of Zeste Homolog 2 Protein
  • Polycomb Repressive Complex 2